Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
作者信息
Hivert Bénédicte, Tamburini Jérome, Vekhoff Anne, Tournilhac Olivier, Leblond Véronique, Morel Pierre
出版信息
Haematologica. 2011 May;96(5):785-8. doi: 10.3324/haematol.2010.029140. Epub 2011 Mar 10.
Abstract
摘要
相似文献
1
Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.国际评分系统在晚期华氏巨球蛋白血症患者中的预后价值及反应
Haematologica. 2011 May;96(5):785-8. doi: 10.3324/haematol.2010.029140. Epub 2011 Mar 10.
2
Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.利妥昔单抗诱导的危及生命的凝血病发生在一名接受氟达拉滨、环磷酰胺和利妥昔单抗联合治疗的华氏巨球蛋白血症患者身上。
Leuk Lymphoma. 2010 Dec;51(12):2288-90. doi: 10.3109/10428194.2010.523127. Epub 2010 Oct 7.
3
Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.
Leuk Lymphoma. 2008 Jun;49(6):1209-11. doi: 10.1080/10428190802007718.
4
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.氟达拉滨、环磷酰胺和利妥昔单抗在华氏巨球蛋白血症挽救治疗中的应用。
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):231-4. doi: 10.1016/j.clml.2013.02.011. Epub 2013 Mar 13.
5
Waldenström macroglobulinemia: my way.华氏巨球蛋白血症：我的方法。
Leuk Lymphoma. 2013 Mar;54(3):464-71. doi: 10.3109/10428194.2012.717173. Epub 2012 Aug 25.
6
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.氟达拉滨联合环磷酰胺和利妥昔单抗治疗巨球蛋白血症：一种有效但骨髓抑制的方案，适用于晚期疾病患者。
Cancer. 2012 Jan 15;118(2):434-43. doi: 10.1002/cncr.26303. Epub 2011 Jul 5.
7
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.奥法木单抗、氟达拉滨和环磷酰胺用于复发/难治性华氏巨球蛋白血症的2期研究。
Leuk Lymphoma. 2017 Jun;58(6):1506-1508. doi: 10.1080/10428194.2016.1233541. Epub 2016 Oct 10.
8
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.地塞米松、利妥昔单抗和环磷酰胺作为华氏巨球蛋白血症的一线治疗：一项2期研究的最终分析
Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420.
9
Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.喷司他丁、环磷酰胺和利妥昔单抗对瓦尔登斯特伦巨球蛋白血症患者是一种安全有效的治疗方法。
Leuk Lymphoma. 2015 Jan;56(1):97-102. doi: 10.3109/10428194.2014.911869. Epub 2014 Jun 25.
10
Rituximab-based treatments in Waldenström's macroglobulinemia.基于利妥昔单抗的治疗方案在华氏巨球蛋白血症中的应用
Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015.
引用本文的文献
1
Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?早期疾病进展是否预示着华氏巨球蛋白血症一线治疗后的生存？
Hematol Oncol. 2022 Aug;40(3):400-408. doi: 10.1002/hon.2996. Epub 2022 May 1.
2
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.症状性华氏巨球蛋白血症患者的进展起始和二次治疗决定其生存。
Blood Adv. 2018 Nov 27;2(22):3102-3111. doi: 10.1182/bloodadvances.2018021287.
3
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.华氏巨球蛋白血症（WM）及相关疾病患者的治疗建议：IWWM - 7共识
Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15.
本文引用的文献
1
Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.异基因造血干细胞移植可使高危华氏巨球蛋白血症患者获得长期完全缓解和治愈。法国骨髓和细胞治疗学会回顾性分析的结果。
Haematologica. 2010 Jun;95(6):950-5. doi: 10.3324/haematol.2009.017814. Epub 2010 Jan 15.
2
Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.利妥昔单抗治疗 4 剂后微小反应对瓦尔登斯特伦巨球蛋白血症的临床价值：东部肿瘤协作组 E3A98 试验的随访。
Br J Haematol. 2009 Dec;147(5):677-80. doi: 10.1111/j.1365-2141.2009.07892.x. Epub 2009 Sep 14.
3
International prognostic scoring system for Waldenstrom macroglobulinemia.华氏巨球蛋白血症国际预后评分系统。
Blood. 2009 Apr 30;113(18):4163-70. doi: 10.1182/blood-2008-08-174961. Epub 2009 Feb 5.
4
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.接受核苷类似物治疗的华氏巨球蛋白血症患者转化和骨髓增生异常综合征/急性白血病的发病率增加。
J Clin Oncol. 2009 Jan 10;27(2):250-5. doi: 10.1200/JCO.2007.15.1530. Epub 2008 Dec 8.
5
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.来自第四届华氏巨球蛋白血症国际研讨会的治疗建议更新
J Clin Oncol. 2009 Jan 1;27(1):120-6. doi: 10.1200/JCO.2008.17.7865. Epub 2008 Dec 1.
6
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.氟达拉滨和利妥昔单抗治疗华氏巨球蛋白血症的长期疗效。
Blood. 2009 Apr 16;113(16):3673-8. doi: 10.1182/blood-2008-09-177329. Epub 2008 Nov 17.
7
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.用 dexamethasone、利妥昔单抗和环磷酰胺对 Waldenström 巨球蛋白血症进行初始治疗。
J Clin Oncol. 2007 Aug 1;25(22):3344-9. doi: 10.1200/JCO.2007.10.9926. Epub 2007 Jun 18.
8
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.来自第三届华氏巨球蛋白血症国际研讨会的评估反应建议更新
Clin Lymphoma Myeloma. 2006 Mar;6(5):380-3. doi: 10.3816/CLM.2006.n.013.
9
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.氟达拉滨联合环磷酰胺治疗华氏巨球蛋白血症：49例患者的治疗结果
Leukemia. 2005 Oct;19(10):1831-4. doi: 10.1038/sj.leu.2403885.
Zotero 插件